Eczema (Atopic Dermatitis) Clinical Trials

A listing of Eczema (Atopic Dermatitis) medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 157 clinical trials
A Study of Lebrikizumab (LY3650150) on Vaccine Response in Adults With Atopic Dermatitis (ADopt-VA)

The reason for this study is to assess the impact of lebrikizumab on vaccine immune response in adult participants with moderate to severe atopic dermatitis (AD).

lebrikizumab
topical agents
eczema
  • 0 views
  • 29 May, 2021
  • 84 locations
A Study to Assess the Effects of Nemolizumab on Cytochrome P450 Substrates in Participants With Moderate-to-Severe Atopic Dermatitis

The purpose of this study is to evaluate the effect of nemolizumab (CD14152) on the pharmacokinetics (PK) of a drug "cocktail" representative of CYP450 (CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4/5 sensitive index substrates) in adult participants with moderateto- severe atopic dermatitis (AD).

  • 0 views
  • 28 Jan, 2021
  • 2 locations
The Role of IL-22/IL-22BP Axis in Atopic Dermatitis

Interleukin 22 (IL-22) is known to be regulated by IL-22 binding protein (IL-22BP), a soluble, inhibitory receptor. The potential role of IL-22BP in atopic dermatitis (AD) is mostly unknown and deserves further investigation. The main objective of this study is to better understand the potential protective role of IL-22BP through …

  • 0 views
  • 27 Jan, 2021
  • 1 location
A First-in-Human Study of CEE321 in Adult Subjects

Open label, non-randomized, uncontrolled, First-in-Human Phase 1 Study in Healthy Subjects and Subjects with Atopic Dermatitis

  • 0 views
  • 05 Apr, 2021
  • 4 locations
Delgocitinib Cream for the Treatment of Moderate to Severe Atopic Dermatitis During 8 Weeks in Adults Adolescents and Children

This is a multi-center, open-label trial to evaluate safety and pharmacokinetics of topical delgocitinib cream applied to pediatric subjects (2-17 years) and adult subjects (18 years and above) with atopic dermatitis.

atopy
  • 244 views
  • 25 Apr, 2021
  • 22 locations
Comparison of Lindioil (Indigo Naturalis Oil Extract) Ointment to Protopic Ointment 0.1% in Treating Atopic Dermatitis

The aims of this study are: Compare the efficacy of Lindioil ointment and Protopic ointment in treating atopic dermatitis. Compare the safety of Lindioil ointment and Protopic ointment in treating atopic dermatitis. Compare the time to relapse after ceasing of treatment of Lindioil ointment and Protopic ointment. Compare the change …

protopic
corticosteroids
tacrolimus
atopy
  • 27 views
  • 23 Jan, 2021
  • 2 locations
Brief Cognitive Behavioral Therapy to Treat Itch Rumination "Itch CBT" in Eczema

The main purpose of this study is to adapt cognitive behavior therapy (CBT) to improve itch in children with eczema.

  • 0 views
  • 13 Mar, 2021
  • 1 location
Jaktinib Hydrochloride Cream For Atopic Dermatitis

This study includes a dose escalation part and a dose extension part.

  • 0 views
  • 26 Jan, 2021
  • 1 location
Study Evaluating the Mechanism of Action of PF-04965842 Monotherapy for Moderate-to-severe Atopic Dermatitis

B7451037 is a randomized, double-blind, placebo-controlled, parallel-group, Phase 2a study to investigate the mechanism of action of PF-04965842 by correlating efficacy outcomes with changes from baseline in key skin and blood biomarkers in adult participants at least 18 years of age with moderate-to-severe atopic dermatitis. Participants will be screened within …

topical agents
pf-04965842
atopy
  • 55 views
  • 03 Apr, 2021
  • 10 locations
Dupilumab in Japanese Patients With Atopic Dermatitis

Primary Objective: To evaluate the efficacy of dupilumab administered concomitantly with topical corticosteroids (TCS) Secondary Objective: To evaluate the efficacy of dupilumab administered concomitantly with TCS. To assess the safety of dupilumab over 16 weeks of treatment when administered concomitantly with TCS in participants. To assess immunogenicity as determined by …

  • 0 views
  • 27 Jan, 2021
  • 5 locations